Atherosclerosis is a chronic inflammatory disease of arterial walls characterized by lipid-laden plaque formation, endothelial dysfunction, and progressive vascular occlusion. It is the pathological substrate underlying coronary artery disease, stroke, and peripheral artery disease.

The gut microbiome contributes to atherosclerosis through at least four mechanistic pathways: (1) TMAO production from dietary choline/carnitine promoting foam cell formation and platelet activation, (2) SCFA depletion removing cardiovascular protection, (3) LPS-driven endotoxemia activating vascular inflammation, and (4) oral bacterial translocation directly colonizing atherosclerotic plaques.

Heavy metals—cadmium, lead, arsenic, mercury, and nickel—converge on endothelial dysfunction through oxidative stress, NO depletion, and mis-metallation of essential metalloenzymes. The landmark Jie et al. 2017 metagenome-wide association study (n=405) achieved 86% AUC in classifying ACVD from microbiome data alone.

Evidence map24 cited passagesInspect provenance +
01
Metallomic Signature

Cadmium (Cd)—Associates with atherosclerosis, CHD, stroke, PAD, and myocardial infarction across 38 studies and ~160,000 subjects. Mechanism: ROS via TNF-alpha, NF-kB p65, NLRP3, endothelial damage via reduced NO and increased endothelin-1 (EDN-1). Physiologic plasma range <1 ug/L, pathologic 5 ug/L.

02
Metallomic Signature

Lead (Pb)—10 ug/dL correlates with CAD, PAD, heart failure, stroke. Mechanism: H2O2 and superoxide generation, eNOS disruption, endothelin-1 elevation, Ca2+ transport alteration, elastin synthesis disruption.

03
Metallomic Signature

Arsenic (As)—Inorganic As associated with CHD, PAD, CAD, atherosclerosis, endothelial dysfunction, stroke. Mechanism: sICAM-1 and sVCAM-1 elevation (adhesion molecule activation), NO reduction, PON-1 decrease.

04
Metallomic Signature

Mercury (Hg)—MeHg exposure linked to LDL oxidation, PLA2 activation, PON-1 inactivation (reduced HDL protection), glutathione depletion.

05
Metallomic Signature

Nickel (Ni)—Urinary nickel in highest quartile associates with 3.57-fold increased CVD risk (NHANES); SOD depletion and glutathione reduction.

06
Metallomic Signature

Mechanistic convergence: All four non-essential metals (Cd, Hg, As, Pb) drive cardiovascular damage through the same five pathways: (1) ROS/oxidative stress and glutathione/SOD/catalase depletion, (2) endothelial dysfunction via NO reduction and endothelin elevation, (3) lipid peroxidation and LDL oxidation, (4) inflammation (IL-6, IL-8, TNF-alpha, COX-2), (

07
Nutritional Immunity Response

CRP—Consistently elevated in atherosclerosis; CANTOS trial confirmed that IL-1-beta inhibition reduces ASCVD events. CRP positively associated with Serratia abundance (P=0.0001) in subclinical CVD.

08
Nutritional Immunity Response

VCAM-1, ICAM-1—Adhesion molecules elevated by arsenic (sICAM-1, sVCAM-1) and TMAO (via PKC/NF-kB pathway),.

09
Enriched Taxa

| Taxon | Role | Evidence | |-------|------|----------| | enterobacteriaceae | TMA lyase gene enrichment; LPS biosynthesis; siderophore iron piracy; 47 MLGs selected for ACVD classifier (AUC 86%) | | | escherichia coli | Multiple MLGs with unique ACVD features; copper homeostasis systems | | | streptococcus spp. | Oral streptococci translocated to gut; enric

10
Depleted Taxa

| Taxon | Role | Evidence | |-------|------|----------| | roseburia | Major butyrate producer—loss removes SCFA-mediated cardiovascular protection | | | faecalibacterium prausnitzii | Butyrate producer—depleted in untreated ACVD patients | | | lachnospiraceae | SCFA producers—reduced butyrate synthesis potential | | | eubacterium spp. | Coprostanol-pro

11
Oral-Plaque Translocation

A distinctive feature of atherosclerosis is the direct colonization of atherosclerotic plaques by oral bacteria:

12
Causal Evidence

Germ-free ApoE-/- mice develop increased atherosclerotic plaques vs. conventionally raised counterparts on chow diet

13
Causal Evidence

Drug confounding is the major consideration: fondaparinux, acarbose, metoprolol, atorvastatin all significantly influence gut microbial genes, reducing classification power

14
Virulence Enzymes and Features

TMA lyases (CutC/D, YeaW/X)—Convert dietary choline, phosphatidylcholine, and L-carnitine to TMA. Enriched in ACVD microbiome. TMAO then inhibits reverse cholesterol transport (ABCG5/G8), upregulates CD36 and SR-A1 in macrophages (foam cell formation), activates NF-kB and NLRP3 inflammasome,.

15
Virulence Enzymes and Features

LPS biosynthesis enzymes—Enriched in ACVD; LPS activates TLR4-mediated NADPH oxidase pathway generating ROS and vascular inflammation via p38MAPK/NF-kB.

16
Virulence Enzymes and Features

Bile salt hydrolase (BSH)—Bacteria with BSH convert primary to secondary bile acids, activating FXR and TGR5 receptors that regulate cholesterol metabolism.

17
Virulence Enzymes and Features

Cholesterol-to-coprostanol conversion—Limited to Eubacterium and Bacteroides genera; depletion of these organisms impairs microbial cholesterol clearance.

18
Ecological State

TMAO elevation—TMAO inhibits reverse cholesterol transport, promotes foam cell formation via CD36/SR-A1 upregulation, activates NLRP3 inflammasome via TXNIP, enhances platelet hyperreactivity through Ca2+ release, and destroys endothelial tight junctions via HMGB1/TLR4 signaling. People with high circulating TMAO have 12% increased CVD risk.

19
Ecological State

SCFA depletion—Reduced butyrate synthesis capacity; loss of GPR41/GPR43-mediated anti-inflammatory and barrier-protective effects; reduced HDAC inhibition.

20
Ecological State

LPS-driven endotoxemia—Metabolic endotoxemia from Enterobacteriaceae-enriched dysbiosis; activates TLR4 on immune cells, triggering pro-inflammatory cascades, foam cell formation, and atherosclerotic plaque progression.

21
Ecological State

Oral-gut translocation—Dual-site dysbiosis: oral periodontitis bacteria seed atherosclerotic plaques while gut dysbiosis produces pro-atherogenic metabolites.

22
Ecological State

Elevated Firmicutes/Bacteroidetes ratio—Hallmark of aging and cardiometabolic disease; associated with TMAO elevation.

23
Multi-omic Integration

Li et al. 2021 demonstrated that integrating gut microbiome, blood biomarkers, and urine metabolomics reveals cross-system interactions in carotid atherosclerosis that single-omic approaches miss:

24
Associated Conditions

The cardiometabolic disease cluster (atherosclerosis-hypertension-T2D-obesity-CKD) shares a remarkably conserved core signature: Enterobacteriaceae enrichment, butyrate-producer depletion, TMAO elevation, and heavy metal burden. Cross-disease features with liver cirrhosis, RA, and T2D were noted in the landmark Jie et al. 2017 study.

Contents1. Metallomic Signature2. Environmental Exposures3. Nutritional Immunity Response4. Taxonomic Analysis5. Virulence Enzymes and Features6. Ecological State7. Associated Conditions8. Open Questions9. Karen's Brain Primitives Active

Metallomic Signature#

Confidence: high

Elevated. Cadmium (cadmium (Cd))—Associates with atherosclerosis, CHD, stroke, PAD, and myocardial infarction across 38 studies and ~160,000 subjects. Mechanism: ROS via TNF-alpha, NF-kB p65, NLRP3, endothelial damage via reduced NO and increased endothelin-1 (EDN-1).

Physiologic plasma range <1 ug/L, pathologic >5 ug/L.[1]Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviewsNucera S, Serra M, Caminiti R et al. · 2024Open reference 1

Lead (lead (Pb))—>10 ug/dL correlates with CAD, PAD, heart failure, stroke. Mechanism: H2O2 and superoxide generation, eNOS disruption, endothelin-1 elevation, calcium(II) (Ca2+) transport alteration, elastin synthesis disruption.[1]Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviewsNucera S, Serra M, Caminiti R et al. · 2024Open reference 1

Arsenic (arsenic (As))—Inorganic As associated with CHD, PAD, CAD, atherosclerosis, endothelial dysfunction, stroke. Mechanism: sICAM-1 and sVCAM-1 elevation (adhesion molecule activation), NO reduction, PON-1 decrease.[1]Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviewsNucera S, Serra M, Caminiti R et al. · 2024Open reference 1

Mercury (mercury)—methylmercury (MeHg) exposure linked to LDL oxidation, PLA2 activation, PON-1 inactivation (reduced HDL protection), glutathione depletion.[1]Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviewsNucera S, Serra M, Caminiti R et al. · 2024Open reference 1

Nickel (nickel (Ni))—Urinary nickel in highest quartile associates with 3.57-fold increased CVD risk (NHANES); SOD depletion and glutathione reduction.[2]Liu 2025 — Nickel Cardio-Metabolic EffectsLiu, Y., Zhang et al. · 2025Open reference 2

Iron (iron (Fe))—Excess iron in atherosclerotic plaques promotes Fenton reactions and LDL oxidation; Enterobacteriaceae iron piracy via siderophores expands pathogenic populations.

Depleted. Glutathione—Depleted by all four non-essential metals through oxidative stress. Zinc—Displaced from metalloenzymes by cadmium and lead; copper (Cu)/zinc (Zn) homeostasis disrupted.

Copper—Homeostasis disrupted by lead exposure; E. coli copper homeostasis systems may confer survival advantage in ACVD gut.

Mechanistic convergence: All four non-essential metals (cadmium, mercury, arsenic, lead) drive cardiovascular damage through the same five pathways: (1) ROS/oxidative stress and glutathione/SOD/catalase depletion, (2) endothelial dysfunction via NO reduction and endothelin elevation, (3) lipid peroxidation and LDL oxidation, (4) inflammation (IL-6, IL-8, TNF-alpha, COX-2), (5) displacement of essential metals (calcium(II), zinc, copper) from physiologic binding sites.[1]Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviewsNucera S, Serra M, Caminiti R et al. · 2024Open reference 1

Environmental Exposures#

Cadmium: Tobacco smoke (primary source for smokers), contaminated food crops (rice, leafy vegetables), occupational exposure. Smokers show significantly higher cadmium (Cd) in blood/urine. Lead: Ubiquitous in soil, food, water, cosmetics, and tobacco.

Lead paint in older housing. Arsenic: Drinking water contamination (EPA standard 10 ug/L); rice; seafood (organic forms less toxic).

Mercury: Seafood (methylmercury (MeHg)), dental amalgams, industrial exposure. Nickel: Dietary (legumes, nuts, whole grains, chocolate), occupational, environmental contamination.

Nutritional Immunity Response#

Confidence: high

Elevated. CRP—Consistently elevated in atherosclerosis; CANTOS trial confirmed that IL-1-beta inhibition reduces ASCVD events.[3]Microbiome and Cardiovascular DiseaseHilde Herrema, Max Nieuwdorp, Albert K. Groen · 2020Open reference 3 CRP positively associated with Serratia abundance (P=0.0001) in subclinical CVD.[4]Gut microbiota and vascular biomarkers in patients without clinical cardiovascular diseasesDaria Kashtanova, Olga Tkacheva, Anna Popenko et al. · 2017Open reference 4

IL-6, TNF-alpha, IL-1-beta, IL-18—Pro-inflammatory cytokines driving atherosclerotic plaque inflammation.

VCAM-1, ICAM-1—Adhesion molecules elevated by arsenic (sICAM-1, sVCAM-1) and TMAO (via PKC/NF-kB pathway).[1]Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviewsNucera S, Serra M, Caminiti R et al. · 2024Open reference 1[5]The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseasesJing Zhen, Zhou Zhou, Meng He et al. · 2023Open reference 5

Hepcidin, calprotectin—Reflecting iron sequestration and neutrophil-mediated inflammation.

Depleted. Glutathione, SOD, catalase—Antioxidant defenses overwhelmed by metal-driven and microbial-driven oxidative stress. PON-1 (paraoxonase-1)—Inactivated by mercury; reduced HDL-protective capacity.

PON-1 decrease also observed with arsenic exposure.

Taxonomic Analysis#

Confidence: high

Enriched Taxa#

TaxonRoleEvidence
EnterobacteriaceaeTMA lyase gene enrichment; LPS biosynthesis; siderophore iron piracy; 47 MLGs selected for ACVD classifier (AUC 86%)[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6
Escherichia coliMultiple MLGs with unique ACVD features; copper homeostasis systems[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6
Streptococcus spp.Oral streptococci translocated to gut; enriched in ACVD and cirrhosis; oral bacteria found in atherosclerotic plaques[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6[7]The oral microbiome in the pathophysiology of cardiovascular diseaseAndrea Tonelli, Evelyn N. Lumngwena, Ntobeko A. B. Ntusi · 2023Open reference 7
Ruminococcus gnavusEnriched in ACVD; pro-inflammatory mucin degrader[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6
[[serratia-marcescensserratia]]Positively associated with CRP (P=0.0001), IMT, and carotid stenosis[4]Gut microbiota and vascular biomarkers in patients without clinical cardiovascular diseasesDaria Kashtanova, Olga Tkacheva, Anna Popenko et al. · 2017Open reference 4
[[lancefieldella-parvulaAtopobium parvulum]]Correlated with triglyceride levels (r=0.39)[8]Network of Interactions Between Gut Microbiome, Host Biomarkers, and Urine Metabolome in Carotid AtherosclerosisRui-Jun Li, Zhu-Ye Jie, Qiang Feng et al. · 2021Open reference 8

Depleted Taxa#

TaxonRoleEvidence
RoseburiaMajor butyrate producer—loss removes SCFA-mediated cardiovascular protection[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6
Faecalibacterium prausnitziiButyrate producer—depleted in untreated ACVD patients[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6
LachnospiraceaeSCFA producers—reduced butyrate synthesis potential[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6
Eubacterium spp.Coprostanol-producing cholesterol-lowering bacteria; conversion rates bimodal in human populations[9]Gut Microbiota and Cardiovascular Disease: Opportunities and ChallengesNegin Kazemian, Morteza Mahmoudi, Frank Halperin et al. · 2020Open reference 9
Parabacteroides distasonisIndole-producing; IPA (indole-3-propionic acid) is atheroprotective; inversely correlated with plaque size[10]Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular diseaseDorothea Katharina Hoffelner, Tim Hendrikx · 2025Open reference 10
Bacteroidetes (Bacteroidota) (phylum)Decreased including Bacteroides and Prevotella in ASCVD vs. controls[3]Microbiome and Cardiovascular DiseaseHilde Herrema, Max Nieuwdorp, Albert K. Groen · 2020Open reference 3

Oral-Plaque Translocation#

A distinctive feature of atherosclerosis is the direct colonization of atherosclerotic plaques by oral bacteria.[7]The oral microbiome in the pathophysiology of cardiovascular diseaseAndrea Tonelli, Evelyn N. Lumngwena, Ntobeko A. B. Ntusi · 2023Open reference 7

Periodontitis bacteria translocate through inflamed periodontium into systemic circulation, directly inoculating plaques. Viridans group streptococci express adhesin B, facilitating platelet aggregation on valve endothelium. Chronic oral inflammation releases pro-inflammatory cytokines causing endothelial dysfunction.

Oral bacterial antigens trigger molecular mimicry—cross-reactive antibodies target atherosclerotic plaques.

Causal Evidence#

Germ-free ApoE-/- mice develop increased atherosclerotic plaques vs. conventionally raised counterparts on chow diet.[3]Microbiome and Cardiovascular DiseaseHilde Herrema, Max Nieuwdorp, Albert K. Groen · 2020Open reference 3 FMT from atherosclerotic mice induces atherosclerosis in recipient mice. Transplantation of pro-inflammatory microbiome into LDLR-/- mice accelerates atherosclerosis.

Drug confounding is the major consideration: fondaparinux, acarbose, metoprolol, atorvastatin all significantly influence gut microbial genes, reducing classification power.[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6

Virulence Enzymes and Features#

Confidence: high

TMA lyases (CutC/D, YeaW/X)—Convert dietary choline, phosphatidylcholine, and L-carnitine to TMA. Enriched in ACVD microbiome. TMAO then inhibits reverse cholesterol transport (ABCG5/G8), upregulates CD36 and SR-A1 in macrophages (foam cell formation), activates NF-kB and NLRP3 inflammasome.[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6[5]The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseasesJing Zhen, Zhou Zhou, Meng He et al. · 2023Open reference 5

Siderophores—Iron acquisition systems enriched in Enterobacteriaceae; competitive iron piracy fuels pathogenic expansion.

LPS biosynthesis enzymes—Enriched in ACVD; LPS activates TLR4-mediated NADPH oxidase pathway generating ROS and vascular inflammation via p38MAPK/NF-kB.[11]Role of Gut Microbiome in Cardiovascular Events: A Systematic ReviewNaushad M. Mansuri, Neelam K. Mann, Shariqa Rizwan et al. · 2022Open reference 11

Bile salt hydrolase (BSH)—Bacteria with BSH convert primary to secondary bile acids, activating FXR and TGR5 receptors that regulate cholesterol metabolism.[9]Gut Microbiota and Cardiovascular Disease: Opportunities and ChallengesNegin Kazemian, Morteza Mahmoudi, Frank Halperin et al. · 2020Open reference 9

Cholesterol-to-coprostanol conversion—Limited to Eubacterium and Bacteroides genera; depletion of these organisms impairs microbial cholesterol clearance.[9]Gut Microbiota and Cardiovascular Disease: Opportunities and ChallengesNegin Kazemian, Morteza Mahmoudi, Frank Halperin et al. · 2020Open reference 9

Ecological State#

Confidence: high

TMAO elevation—TMAO inhibits reverse cholesterol transport, promotes foam cell formation via CD36/SR-A1 upregulation, activates NLRP3 inflammasome via TXNIP, enhances platelet hyperreactivity through calcium(II) (Ca2+) release, and destroys endothelial tight junctions via HMGB1/TLR4 signaling.[5]The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseasesJing Zhen, Zhou Zhou, Meng He et al. · 2023Open reference 5

People with high circulating TMAO have 12% increased CVD risk.[11]Role of Gut Microbiome in Cardiovascular Events: A Systematic ReviewNaushad M. Mansuri, Neelam K. Mann, Shariqa Rizwan et al. · 2022Open reference 11

SCFA depletion—Reduced butyrate synthesis capacity; loss of GPR41/GPR43-mediated anti-inflammatory and barrier-protective effects; reduced HDAC inhibition.[10]Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular diseaseDorothea Katharina Hoffelner, Tim Hendrikx · 2025Open reference 10

LPS-driven endotoxemia—Metabolic endotoxemia from Enterobacteriaceae-enriched dysbiosis; activates TLR4 on immune cells, triggering pro-inflammatory cascades, foam cell formation, and atherosclerotic plaque progression.[7]The oral microbiome in the pathophysiology of cardiovascular diseaseAndrea Tonelli, Evelyn N. Lumngwena, Ntobeko A. B. Ntusi · 2023Open reference 7

Foam cell formation—TMAO upregulates scavenger receptors, LPS activates macrophages, and oxidized LDL (from metal-catalyzed lipid peroxidation) drives cholesterol accumulation in arterial walls.

Oral-gut translocation—Dual-site dysbiosis: oral periodontitis bacteria seed atherosclerotic plaques while gut dysbiosis produces pro-atherogenic metabolites.[7]The oral microbiome in the pathophysiology of cardiovascular diseaseAndrea Tonelli, Evelyn N. Lumngwena, Ntobeko A. B. Ntusi · 2023Open reference 7 Elevated Firmicutes/Bacteroidetes ratio—Hallmark of aging and cardiometabolic disease; associated with TMAO elevation.[11]Role of Gut Microbiome in Cardiovascular Events: A Systematic ReviewNaushad M. Mansuri, Neelam K. Mann, Shariqa Rizwan et al. · 2022Open reference 11

Multi-omic Integration#

lithium (Li) et al. 2021 demonstrated that integrating gut microbiome, blood biomarkers, and urine metabolomics reveals cross-system interactions in carotid atherosclerosis that single-omic approaches miss.[8]Network of Interactions Between Gut Microbiome, Host Biomarkers, and Urine Metabolome in Carotid AtherosclerosisRui-Jun Li, Zhu-Ye Jie, Qiang Feng et al. · 2021Open reference 8

GGT, serum ferritin, ALT, monocytes, ApoB most strongly associated with microbiome composition. Eubacterium, F. prausnitzii, Ruminococcus associated with healthy liver function. Clostridium bolteae, Tyzzerella nexilis, R. gnavus associated with liver disease biomarkers.

Associated Conditions#

ConditionShared MetalsShared TaxaShared EcologyOverlap Score
Hypertensionlead (Pb), cadmium (Cd), nickel (Ni)Enterobacteriaceae, Roseburia depleted, Lachnospiraceae depletedTMAO elevation, SCFA depletion, LPS endotoxemia0.78
Chronic Kidney Diseaselead, cadmiumEnterobacteriaceae, Lachnospiraceae depletedTMAO elevation, SCFA depletion0.60
Type 2 Diabeteslead, cadmium, iron (Fe)Enterobacteriaceae, F. prausnitzii depleted, Lachnospiraceae depleted, EggerthellaElevated F/B ratio, SCFA depletion, LPS endotoxemia0.68
Obesitylead, cadmium, nickelEnterobacteriaceae, F. prausnitzii depleted, Roseburia depletedElevated F/B ratio, SCFA depletion0.58

The cardiometabolic disease cluster (atherosclerosis-hypertension-T2D-obesity-CKD) shares a remarkably conserved core signature: Enterobacteriaceae enrichment, butyrate-producer depletion, TMAO elevation, and heavy metal burden. Cross-disease features with liver cirrhosis, RA, and T2D were noted in the landmark Jie et al. 2017 study.[6]The gut microbiome in atherosclerotic cardiovascular diseaseZhuye Jie, Huihua Xia, Shi-Long Zhong et al. · 2017Open reference 6

Open Questions#

Unresolved questions identified by the current evidence record.

01Can TMA lyase inhibitors (3,3-DMB or structural analogs) reduce TMAO and slow plaque progression in humans?

The current WikiBiome record identifies this as an unresolved evidence gap.

02What is the relative contribution of oral vs. gut dysbiosis to atherosclerotic plaque formation and instability?

The current WikiBiome record identifies this as an unresolved evidence gap.

03Does chelation of cadmium (Cd)/lead (Pb)/As combined with microbiome restoration produce synergistic cardiovascular benefit?

The current WikiBiome record identifies this as an unresolved evidence gap.

04Can coprostanol-producing bacteria (Eubacterium, Bacteroides) be supplemented to enhance microbial cholesterol clearance?

The current WikiBiome record identifies this as an unresolved evidence gap.

05How much of the ACVD microbiome signature is drug-confounded (statins, antihypertensives, anticoagulants)?

The current WikiBiome record identifies this as an unresolved evidence gap.

06Does Parabacteroides distasonis supplementation (IPA production) protect against plaque growth?

The current WikiBiome record identifies this as an unresolved evidence gap.

Karen's Brain Primitives Active#

Primitive 1 (Metals as Selective Pressures): cadmium (Cd), lead (Pb), arsenic (As), mercury (Hg), and nickel (Ni) all contribute to atherosclerosis through shared oxidative stress and endothelial dysfunction pathways; these metals also select for metal-tolerant gut organisms.

Primitive 3 (Mis-metallation and Toxic Metal Entry): All four non-essential metals displace essential metals—cadmium/lead displace calcium(II) (Ca2+) and zinc (Zn), mercury disrupts disulfide bonds, As targets thiol groups—directly impairing cardiovascular metalloenzymes (eNOS, SOD, PON-1).

Primitive 4 (Microbial Metal Dependencies as Achilles' Heels): Enterobacteriaceae iron piracy via siderophores fuels their expansion; E. coli copper homeostasis systems confer survival advantage in the ACVD gut.

Primitive 5 (Two-Sided Ecological Engineering): Suppress TMAO-producing Enterobacteriaceae AND restore butyrate-producing Roseburia/Faecalibacterium/Eubacterium to re-engage SCFA-mediated cardiovascular protection and cholesterol clearance.

Primitive 8 (Siderophore Competition and Iron Ecology): Iron ecology is central—siderophore-producing Enterobacteriaceae expansion in ACVD represents competitive iron acquisition driving pathogenic dominance.

Generated evidence record

References 11

Numbered by first appearance in the article, then reconciled with its declared source list.

  1. 1

    Nucera S, Serra M, Caminiti R et al. (2024). Nucera 2024 — Non-essential heavy metal effects in cardiovascular diseases: overview of systematic reviews. Frontiers in Cardiovascular Medicine.

  2. 2

    Liu, Y., Zhang et al. (2025). Liu 2025 — Nickel Cardio-Metabolic Effects. Cardiovascular Toxicology.

  3. 3

    Hilde Herrema, Max Nieuwdorp, Albert K. Groen (2020). Microbiome and Cardiovascular Disease. Handbook of Experimental Pharmacology (Prevention and Treatment of Atherosclerosis).

  4. 4

    Daria Kashtanova, Olga Tkacheva, Anna Popenko et al. (2017). Gut microbiota and vascular biomarkers in patients without clinical cardiovascular diseases. Artery Research.

  5. 5

    Jing Zhen, Zhou Zhou, Meng He et al. (2023). The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Frontiers in Endocrinology.

  6. 6

    Zhuye Jie, Huihua Xia, Shi-Long Zhong et al. (2017). The gut microbiome in atherosclerotic cardiovascular disease. Nature Communications.

  7. 7

    Andrea Tonelli, Evelyn N. Lumngwena, Ntobeko A. B. Ntusi (2023). The oral microbiome in the pathophysiology of cardiovascular disease. Nature Reviews Cardiology.

  8. 8

    Rui-Jun Li, Zhu-Ye Jie, Qiang Feng et al. (2021). Network of Interactions Between Gut Microbiome, Host Biomarkers, and Urine Metabolome in Carotid Atherosclerosis. Frontiers in Cellular and Infection Microbiology.

  9. 9

    Negin Kazemian, Morteza Mahmoudi, Frank Halperin et al. (2020). Gut Microbiota and Cardiovascular Disease: Opportunities and Challenges. Microbiome.

  10. 10

    Dorothea Katharina Hoffelner, Tim Hendrikx (2025). Emerging therapy targets to modulate microbiome-mediated effects evident in cardiovascular disease. Frontiers in Cardiovascular Medicine.

  11. 11

    Naushad M. Mansuri, Neelam K. Mann, Shariqa Rizwan et al. (2022). Role of Gut Microbiome in Cardiovascular Events: A Systematic Review. Cureus.

Knowledge graph

Article network

Researcher discussion

Connect the evidence

Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.

0 posts

No discussion yet. Start with a precise question or a source-backed observation.

Transparent record

Activity and accepted changes

Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.

4 events
  1. published revision

    Reconcile current taxonomic identities

    Karen Pendergrass · +2 −2

    Inspect exact Git diff ↗
  2. published revision

    massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers

    WikiBiome Deploy Bot · +51 −51

    Inspect exact Git diff ↗
  3. published revision

    ingest: 87 papers (17 endometriosis, 67 erectile dysfunction, 3 cross-condition)

    WikiBiome Deploy Bot · +2 −2

    Inspect exact Git diff ↗
  4. published revision

    pre-overnight checkpoint 2026-04-18

    WikiBiome Deploy Bot · +230 −0

    Inspect exact Git diff ↗
Continue exploring

Every article is a doorway.

Generated from the WikiBiome Markdown vault and reconciled against its source registry.

11 references · 0 backlinks · 12 indexed topics